ROSWELL PARK CANCER INSTITUTE

CLEAR biomarker analyses show Lenvatinib + Pembrolizumab (L+P) significantly improved efficacy over Sunitinib in advanced RCC. No associations found between PD-L1 levels, gene-signature scores, or molecular subtypes with PFS for L+P. Sunitinib showed shorter PFS with high proliferation and MYC signature scores, longer with high angiogenesis scores. Six new molecular subtypes defined, with no association to PFS for either treatment.

At the STRIPE Annual Meeting & Consensus Workshop, ASP announced the inaugural STRIPE Double Helix Awards, recognizing excellence in pharmacogenomics through collaboration and outstanding achievement. Recipients include Kristine Ashcraft, Cynthia Bens, Burns C. Blaxall, Philip Empey, Jose Estabil, Bernard Esquivel, Christine Formea, Blaine Groat, Daniel Hertz, Carrie Hoefer, Geoff Hollett, J. Shawn Jones, Raymond Lorenz, Ryan Nelson, Micheal Pacanowski, Jai N. Patel, Victoria Pratt, Bronwyn Ramey, Sharmeen Roy, Robert Schuck, April Schultz, Jeffrey A. Shaman, Sharon Shriver, Patrick Silva, D. Max Smith, Annette Taylor, Wrenda Teeple, McKenna Tennant, Kelly E. Caudle, Emily Cicali, Andrea Gaedigk, Houda Houchad, Pamala Jacobson, Teri E. Klein, Akinyemi Oni-Orisan, Natasha Petry, Bani Tamraz, Kristin Wiisanen, and Michelle Whirl-Carrillo. Organizations honored include the Golden Helix Foundation, Department of Veteran Affairs - National Pharmacogenomics Program, and Advocates for Universal DPD/DPYD Testing.